Table of Contents Title of each classTrading Symbol(s)Name of each exchange on which registered Common stock, par value $0.0001 per share ABOS The Nasdaq Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transiti ...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2021 Earnings Conference Call March 28, 2022 4:30 AM ET Company Participants John Woolford - IR, Westwicke Daniel O'Connell - President & CEO Eric Siemers - Chief Medical Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participants Alex Park - Stifel Jason Zemansky - Bank of America Judah Frommer - Credit Suisse Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the ...

Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-40551 Acumen Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delawa ...